Benzinga
Benzinga
Benzinga
sábado, septiembre 12

REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc.

RVPHOTCQB
Trade with Public
Trade with Public
$0.3521
al cierre: May 22, 5:00 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpciones

REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc. Analyst Price Targets

Wall Street analyst price targets and consensus rating for REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc. (RVPH).

Price Target Range — 11 Quarters

Analyst Consensus — 8 Analysts

6Buy
2Hold
Consensus RatingBuy# Analysts8Avg. Consensus PT$135Upside to Avg. PT+25157.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →
DateFirmAnalystActionRating ChangePrice Target
Apr 8, 2026Maxim GroupJason McCarthyDowngradeBuy→Hold—
Mar 31, 2026Roth CapitalBoobalan PachaiyappanPT CutBuy$2→$1
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Maxim Group Downgrades Reviva Pharmaceuticals to Hold

Maxim Group analyst Jason McCarthy downgrades Reviva Pharmaceuticals (NASDAQ:RVPH) from Buy to Hold.
Benzinga Newsdesk

PRO
Watching Reviva Pharmaceuticals; Zacks Small-Cap Research Gives Stock $7 Price Valuation

Benzinga Newsdesk

PRO
D. Boral Capital Downgrades Reviva Pharmaceuticals to Hold

D. Boral Capital analyst Jason Kolbert downgrades Reviva Pharmaceuticals (NASDAQ:RVPH) from Buy to Hold.
Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains $2 price target.
Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains $2 price target.
Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains $2 price target.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved